Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries

Published:2017-12-13 Issue:3 Volume:57 Page:499-507
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:

Author:

Choy Ernest¹,Caporali Roberto²,Xavier Ricardo³,Fautrel Bruno⁴,Sanmarti Raimón⁵,Bao Min⁶,Bernasconi Corrado⁷,Pethö-Schramm Attila⁷

Affiliation:

1. CREATE Centre, Division of Infection and Immunity, Cardiff University, Cardiff, UK

2. Division of Rheumatology, University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy

3. Department of Medicine, Universidade Federal do Rio Grande do Sul Porto Alegre, Rio Grande do Sul, Brazil

4. Department of Rheumatology, APHP, Pitie Salpetriere Hospital, Pierre and Marie Curie University, Paris, France

5. Department of Rheumatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain

6. Genentech, South San Francisco, CA, USA

7. F. Hoffmann-La Roche, Basel, Switzerland

Funder

F. Hoffmann-La Roche

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/57/3/499/24499531/kex443.pdf

Reference19 articles.

1. Interleukin-6 signalling: more than Jaks and STATs;Eulenfeld;Eur J Cell Biol,2012

2. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial;Smolen;Lancet,2008

3. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study;Genovese;Arthritis Rheum,2008

4. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial;Emery;Ann Rheum Dis,2008

5. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study;Jones;Ann Rheum Dis,2010

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Persistence on subcutaneous tocilizumab as monotherapy or in combination with synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients in Greece (EMBRACE study): a multicenter, post-marketing, non-interventional, observational trial;Clinical Rheumatology;2024-03-12

2. Effectiveness and safety of sarilumab in patients with rheumatoid arthritis: A multicenter, retrospective, inverse probability of treatment-weighted analysis based on the FRAB-registry;Clinical Rheumatology;2024-01-06

3. Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: A phase Ia randomized placebo-controlled study;Frontiers in Immunology;2023-02-28

4. Tocilizumab as a first-line biologic treatment in rheumatoid arthritis patients – the impact of concomitant methotrexate treatment and Rheumatic Disease Comorbidity Index on the clinical response – results from the multicenter observational ACT-POL study;Rheumatology;2022-04-30

5. Real-world evidence on methotrexate-free subcutaneous tocilizumab therapy in patients with rheumatoid arthritis: 24-week data from the SIMPACT study;Rheumatology Advances in Practice;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3